Multimodality treatment of malignant pleural mesothelioma: evolving patient selection criteria using scores

Eur J Cardiothorac Surg. 2022 Jul 11;62(2):ezac153. doi: 10.1093/ejcts/ezac153.

Authors

Servet Bölükbas¹, Natalie Baldes¹, Mir Alireza Hoda², Michael Eberlein³

Affiliations

¹ Department of Thoracic Surgery, KEM I Evang. Kliniken Essen-Mitte, Essen, Germany.
² Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria.
³ Division of Pulmonary, Critical Care and Occupational Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

PMID: 35349643
DOI: 10.1093/ejcts/ezac153

No abstract available

Keywords: Malignant pleural mesothelioma; Patient selection; Surgery; Treatment allocation.

Publication types

Editorial
Comment

MeSH terms

Combined Modality Therapy
Humans
Mesothelioma* / diagnosis
Mesothelioma* / pathology
Mesothelioma* / therapy
Mesothelioma, Malignant*
Patient Selection
Pleural Neoplasms* / diagnosis
Pleural Neoplasms* / pathology
Pleural Neoplasms* / therapy
Prognosis